Clinical Trials List
2023-01-23 - 2027-10-13
Phase I
Recruiting2
ICD-10C83.38
Diffuse large B-cell lymphoma, lymph nodes of multiple sites
ICD-10C84.68
Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites
ICD-10C84.78
Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites
ICD-10C85.20
Mediastinal (thymic) large B-cell lymphoma, unspecified site
ICD-10C85.21
Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck
ICD-10C85.22
Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes
ICD-10C85.23
Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes
ICD-10C85.24
Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb
ICD-10C85.25
Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb
ICD-10C85.26
Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes
ICD-10C85.27
Mediastinal (thymic) large B-cell lymphoma, spleen
ICD-10C85.28
Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites
ICD-10C85.29
Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9200.08
Reticulosarcoma, lymph nodes of multiple sites
-
-
Trial Applicant
Pharmaceutical Research Associates Taiwan Inc.
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/14
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
9 participants
-
Global
56 participants
